PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Negative EBIT growth while GNPX is at 13.33%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-35.03%
Negative operating income growth while GNPX is at 13.33%. Joel Greenblatt would press for urgent turnaround measures.
-37.55%
Negative net income growth while GNPX stands at 12.63%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-34.88%
Negative EPS growth while GNPX is at 16.91%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-34.88%
Negative diluted EPS growth while GNPX is at 16.91%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
2.03%
Share reduction more than 1.5x GNPX's 5.10%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
2.03%
Diluted share reduction more than 1.5x GNPX's 5.07%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Positive OCF growth while GNPX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
9.65%
Positive FCF growth while GNPX is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.42%
Positive long-term OCF/share growth while GNPX is negative. John Neff would see a structural advantage in sustained cash generation.
54.54%
5Y OCF/share CAGR above 1.5x GNPX's 32.38%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-31.27%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
85.15%
Similar net income/share CAGR to GNPX's 84.13%. Walter Schloss would see parallel tailwinds or expansions for both firms.
56.20%
5Y net income/share CAGR at 75-90% of GNPX's 65.84%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
-42.46%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-24.53%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-57.00%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-54.63%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.07%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.00%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
41.18%
We increase R&D while GNPX cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
22.12%
SG&A growth well above GNPX's 2.47%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.